Analyst Conference Summary

biotechnology

conference date: February 26, 2026 @ 5:30 AM Pacific Time
for quarter ending: December 31, 2025 (fourth quarter, Q4 2025)

Forward-looking statements

Overview: Mixed results, good y/y growth, optimistic about 2026.

Basic data (GAAP):

Revenue was $60 million, down 48% sequentially from $115 million, and up 40% from $43 million year-earlier.

Net Income was $45 million, down 62% sequentially from $117 million, and up from negative $31 million year-earlier.

EPS (Earnings per Share), diluted, were $2.12, down 63% sequentially from $5.68, and up from negative $1.64 year-earlier.

Guidance:

2026 revenue $245 to $285 million, Non-GAAP EPS $8.00 to $9.00.

Conference Highlights:

CEO Todd Davis said, "We delivered strong fourth quarter results, exceeding our initial full-year adjusted EPS guidance by approximately 30%. This growth was driven by better-than-expected performance across several products in our royalty portfolio, including the successful out-licensing and partner launch of Zelsuvmi. These results highlight the strength of our team and their ability to invest in high-value assets that address significant unmet clinical needs. As we enter 2026, we have a strong balance sheet and are well positioned to execute on our broad pipeline of investment opportunities that we believe position us to continue driving growth and creating long-term shareholder value."

Revenue consisted of $41 million for royalty assets; $10 million from financial royalty assets; $7.8 million Captisol; and $1.3 million contract and other.

In Q4 2025, re Filspari (sparsentan) for proteinuria from primary immunoglobin A nephropathy, which Ligand has licenced to Travere, with Renalys. Chugai is purchasing Renalys, and so rights to commercialize in Japan, S. Korea, and Taiwan. In November 2025 topline positive results for IgAN were announced. Plans to submit an NDA in Japan. But in the U.S. the FDA extended the review timeline for focal sgemental glomerulosclerosis, with PDUFA now April 13, 2026. Product sales in the U.S. reached $103 million in Q4 2025.

In January 2026 Nuance Pharma announced the National Medical Products Administration (NMPA) of China accepted for review the NDA for Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease.

In December 2025 Qtorin Rapamycin reported positive topline results in the Phase 2 study in cutaneous venous malformations. The FDA granted Fast Track status for treating angiokeratomas. In February Palvella announced positive Phase 3 topline results for microcystic LMs, so an NDA is planned.

In Q4 2025 Sanofi announced the FDA accepted for expedited review the sBLA for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D. In January the FDA accepted it for priority review with PDUFA April 29, 2025. And in January 2026 the EU granted approval.

On November 6, 2025, UroGen announced it made the strategic decision to discontinue development of UGN-301 (zalifrelimab) and provided notice of termination to Agenus. While the Phase 1 study confirmed proof of concept, its overall clinical profile did not meet internal benchmarks for advancement.

In December 2025 Leona Bio announced that it acquired the development and commercialization rights to lasofoxifene. It is in a registrational Phase 3 trial for the treatment of metastatic breast cancer. The trial is greater than 50% enrolled with data expected in mid-2027. Ligand is entitled to a tiered 6-10% royalty on future net sales of lasofoxifene.

Ligand had $1 billion in deployable capital at the end of 2025.

In Q1 2026 launched an improved portfolio management process.

Cash and equivalents ended at $733 million, up sequentially from $664 million.

Non-GAAP diluted EPS was $2.02, down sequentially from $3.09, and up from $1.27 year-earlier.

Operating costs of $46 million consisted of: $3 million cost of goods sold, $8 million amortization of intangibles, $4 million R&D, $25 million G&A, $6 million fair value adjustments. Leaving income from operations of $14 million. Gain from short-term investments $22 million; change in equity investments $15 million; interest $5 million; other income $1 million. Income tax $12 million.

For full year 2025, revenue was $268 million, up from $167 million in 2024. Net income was $124 million and GAAP EPS was $6.13. Cash and equivalents ended at $733 million.

Q&A selective summary:

Royalty portfolio 2026 expected updates? Late stage pipeline is active. Listed trials. Should be robust updates over 2026. We are also accelerating the addition of late stage assets.

We have another ten opportunities on our list at present.

Tzield royalty rate is lower than our other partnerships, but it is potentially a very large revenue generator. Sanofi is building out that market of presymptomatic diabetes patients.

FSGS royalties and guidance range? We assumed modest FSGS royalties, $4 million. The delay in the FDA desision had minimum impact on our guidance. It could contribute more in 2027 and beyond.

Filspari market opportunities outside U.S.? Around a billion dollars each in FSGS and Igan. We get a 9% royalty. Dependant on approval and pricing.

General IPO and M&A spaces? Okay market right now, better than 2 years ago. In any case royalty financing is growing rapidly in this space. Most CFOs now understand it as a source of funding. Our investments are long term and attached to the product lifecyle.

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: